|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Supportive Care in Cancer Treatment - Some First-Generation Products Proving Difficult to Dislodge
Datamonitor, Oct 2006, Pages: 233
Supportive care is used to prevent or treat the adverse effects that arise as a result of cancer treatment, particularly chemotherapy. While newer molecular targeted therapies do not exist without some toxicity, this is not as severe as that associated with traditional cytotoxics. A rising incidence of cancer worldwide will mean that supportive care market will increase both size and relevance.
Scope of this title:
-Treatment trends in the use of supportive care pharmacotherapy, including its association with major tumor types and therapy regimens
-Analysis of brand preference within four supportive care pharmacotherapy drug classes based on a survey of 180 physicians across the seven markets
-Physician awareness and use of various supportive care guidelines, including those from the NCCN, ASCO and EORTC
-Ranking of the greatest areas of unmet need within the supportive care market and the likelihood of key future scenarios occurring
Highlights of this title:
Approximately 7080% of all cancer patients who receive cytotoxics suffer nausea and/or vomiting, which has led to widespread acceptance of anti-emetic strategies as an integral component of chemotherapy treatment. In particular, the ubiquitous use of serotonin antagonists is evidenced by the number of products in this drug class.
Incidence of cytopenias is dependent on the use of chemotherapy and the nature of the disease, with hematological malignancies requiring greater supportive care measures. The biologic nature of growth factors used in treatment has translated into high therapy costs, which has somewhat restricted their use in the EU and surprisingly, in the US.
A major focus of current clinical research is the viability of bisphosphonates in the adjuvant setting, to prevent bone metastases prior to their formation. If trial results prove encouraging, a major commercial opportunity exists for those drug developers willing to become involved, particularly if one of the big four tumor types is targeted.
Reasons to order your copy:
-Identify key factors that influence prescribing patterns for supportive care pharmacotherapy
-Examine the significant unmet needs in the supportive care market and identify opportunities for new product development
-Enhance commercial positioning by increasing understanding of current dynamics within the supportive care market
Customers who bought this item also bought
Pipeline/Commercial Insight: Supportive Care In Oncology - Significant Growth Opportunities Exist In New Supportive Care Indications
Target Product Profiles 2008: Physician Insights on Key Attributes - Chemotherapy-Induced Nausea and Vomiting
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Bisphosphonates and Other Bone-Targeting Compounds in the Treatment of Cancer
Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
Medical Review Criteria Guidelines for Managing Care, 8th edition. (2009 Update)
Digestive System Nausea and Vomiting
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Stakeholder Insight: Osteoporosis - Generic Alendronate Further Establishes Oral Bisphosphonates as Gold Standard
Cancer Chemotherapy: Basic Science to the Clinic
Bisphosphonates Update - The Treatment and Prevention of Bone Metastases in Breast and Prostate Cancer
Trends in Cancer Treatment Drugs
|
|
|
|
